Europe's Biggest Biotech Bet Just Got a Lot Bigger

When a top-five pharma company puts money into your fund, it's not just a financial bet. It's a signal that the deal flow is real and the science is worth watching.

The geographic split is interesting too. About 60% of the capital came from European investors, with 40% from North America. That ratio matters because it shows European institutions are actually backing their own ecosystem, not just outsourcing the job to American VCs.

Forbion Didn't Get Here Overnight

This is the part of the story that separates Forbion from a lucky one-off.

The firm spun out of ABN AMRO in 2006 with about €200 million and a portfolio of 26 companies. Two decades later, it manages approximately €7.5 billion and has financed 142 companies, including 37 it helped found from scratch. That's not growth; that's a compounding machine.

The exit track record backs it up. Forbion was an early backer of Replimune, which went public on NASDAQ and raised over $100 million. It invested in HOOKIPA Pharma ($84 million IPO). On the M&A side, Prexton Therapeutics sold to Lundbeck for $1.1 billion, and Rigontec was acquired by Merck for $554 million.

The firm claims a consistent record of top-quartile performance, which in venture capital is like saying you've made the playoffs 20 years in a row. Institutional investors don't just notice that; they line up for it.

Why This Matters Beyond Forbion

European biotech venture capital in 2025 and 2026 has been a study in contradictions. The science is strong. The talent pool is deep. But the funding environment is, to put it charitably, selective.

Deal counts have been flat. Capital is concentrating into fewer, bigger rounds instead of spreading across hundreds of early-stage bets. The UK remains Europe's top biotech financing market, though even its equity fundraising fell sharply from 2024 levels. Early-stage funds, the ones that seed the companies of tomorrow, are still struggling to raise capital across the continent.

Forbion's mega-raise is encouraging, but it also highlights a structural imbalance. The best-known managers with proven track records (Forbion, Sofinnova, Medicxi) can raise enormous funds. Meanwhile, newer and smaller firms face a barren landscape. It's a bit like how the top soccer clubs keep getting richer while lower-league teams can barely pay their electricity bills.

But one firm's success doesn't solve Europe's broader challenges: thin public markets, regulatory fragmentation, and a persistent brain drain to the U.S.

The Bigger Picture

Forbion itself acknowledged the tension in its own framing. The firm described its new capital as "significant dry powder" in a market facing a "general shortage of capital." Translation: we have money because most others don't. That's a competitive advantage, but it's also a warning sign for the ecosystem.

The investor sentiment in European biotech right now is best described as cautiously constructive. Big institutions are willing to back high-conviction platforms with real clinical data and experienced teams. But they're not writing blank checks. Every investment needs to clear a higher bar than it did three years ago.

For the 30 or so companies that will receive Forbion's backing, this is unambiguously great news. For European biotech as a whole, it's a more complicated story: proof that world-class capital formation is possible on this side of the Atlantic, paired with the uncomfortable reality that it still depends on a handful of elite firms rather than a thriving, broad-based ecosystem.

Europe's biotech gap isn't going to close with one fund, no matter how large. But €2.3 billion is a pretty convincing down payment.

The Drug That Could Rewrite How We Treat the Most Common Blood Cancer

AbbVie and Genmab's epcoritamab just delivered a 51% reduction in disease progression when added to frontline chemo for the most common aggressive lymphoma. After 30 years of the same standard of care, the first-line DLBCL playbook may finally be getting a rewrite.